The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Open accessAbstract
BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients. METHODS: We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics. RESULTS: A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden. CONCLUSIONS: In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,444
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293
Self-citationTopp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 914
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,004
Kunz, A., Gern, U., Schmitt, A., Neuber, B., Wang, L., Hückelhoven-Krauss, A., Michels, B., Hofmann, S., Müller-Tidow, C., Dreger, P., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.02.003 · Cited by 54
Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
Dalle, I. A., Jabbour, E. J., & Short, N. J. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720910023 · Cited by 54
Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., Leng, Y., Ren, A., Liu, X., Zhang, Z., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01178-z · Cited by 54
Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
Perera, O. M., Thomas, P. B., Risbridger, G. P., Taylor, R. A., Azad, A., Hofman, M. S., Williams, E. D., & Vela, I. (2022) · Cancers · doi:10.3390/cancers14030503 · Cited by 54
Ruggiero, E., Carnevale, E., Prodeus, A., Magnani, Z. I., Camisa, B., Merelli, I., Politano, C., Stasi, L., Potenza, A., Cianciotti, B. C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8027 · Cited by 58
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
Patel, R. P., Ghilardi, G., Zhang, Y., Chiang, Y., Xie, W., Guruprasad, P., Kim, K. H., Chun, I., Angelos, M. G., Pajarillo, R., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn6509 · Cited by 55
Self-citationCaruso, H. G., Tanaka, R., Liang, J., Ling, X., Sabbagh, A., Henry, V. K., Collier, T. L., & Heimberger, A. B. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03311-y · Cited by 54
Gut microbiome and CAR-T therapy
Abid, M. B., Shah, N. N., Maatman, T. C., & Hari, P. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0155-8 · Cited by 57
Greenbaum, U., Mahadeo, K. M., Kebriaei, P., Shpall, E. J., & Saini, N. Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01594 · Cited by 56
Liu, P., Liu, M., Lyu, C., Lu, W., Cui, R., Wang, J., Li, Q., Mou, N., Deng, Q., & Yang, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.573822 · Cited by 54
Chen, Y., Li, R., Shang, S., Yang, X., Li, L., Wang, W., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623610 · Cited by 61
Self-citationCAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update
Cohen, A. D. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200889 · Cited by 54
Kuhn, N. F., Lopez, A. V., Li, X., Cai, W., Daniyan, A. F., & Brentjens, R. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19833-3 · Cited by 54
Self-citationThe cure of leukemia through the optimist's prism
Kantarjian, H. M., Jain, N., Garcia‐Manero, G., Welch, M. A., Ravandi, F., Wierda, W. G., & Jabbour, E. J. (2021) · Cancer · doi:10.1002/cncr.33933 · Cited by 54
Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance
Muraoka, D., Harada, N., Shiku, H., & Akiyoshi, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.004 · Cited by 54
Li, Q., Xu, L., Zhu, J., Zhong, Y., Yang, J., Wang, J., & Tan, H. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/7530794 · Cited by 56
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Huang, S., Wang, X., Wang, Y., Wang, Y., Fang, C., Wang, Y., Chen, S., Chen, R., Lei, T., Zhang, Y., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01783-1 · Cited by 56
Self-citationJabbour, E. J., Gökbuget, N., Advani, A. S., Stelljes, M., Stock, W., Liedtke, M., Martinelli, G., O'Brien, S. M., Wang, T., Laird, A., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106283 · Cited by 53
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
Hefazi, M., & Litzow, M. R. (2018) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s170351 · Cited by 53
Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
Cronk, R. J., Zurko, J. C., & Shah, N. N. (2020) · Cancers · doi:10.3390/cancers12092523 · Cited by 53
Toxicities following CAR-T therapy for hematological malignancies
Hernani, R., Benzaquen, A. O., & Solano, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102479 · Cited by 55
Locke, F. L., Munoz, J. L., Tees, M. T., Lekakis, L. J., de Vos, S., Nath, R., Stevens, D. A., Malik, S. A., Shouse, G., Hamadani, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01933 · Cited by 52
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
Yi, F., Cohen, T., Zimmerman, N., Dündar, F., Zumbo, P., Eltilib, R., Brophy, E. J., Arkin, H., Feucht, J., Gormally, M. V., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01009-x · Cited by 55
Self-citationRotolo, R., Leuci, V., Donini, C., Cykowska, A., Gammaitoni, L., Medico, G., Valabrega, G., Aglietta, M., & Sangiolo, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112839 · Cited by 53
Stimuli-responsive nanoparticle-assisted immunotherapy: a new weapon against solid tumours
Angelis, B. D., Depalo, N., Petronella, F., Quintarelli, C., Curri, M. L., Pani, R., Calogero, A., Locatelli, F., & Sio, L. D. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02246e · Cited by 53
Hong, R., Hu, Y., & Huang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627764 · Cited by 52
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
Marvin‐Peek, J., Savani, B. N., Oluwole, O. O., & Dholaria, B. (2022) · Cancers · doi:10.3390/cancers14030497 · Cited by 52
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinicPreprint
Bewersdorf, J. P., & Abdel-Wahab, O. I. (2022) · Genes & Development · doi:10.1101/gad.349368.122 · Cited by 53
Myers, R. M., Shah, N. N., & Pulsipher, M. A. (2022) · Blood · doi:10.1182/blood.2022016937 · Cited by 51
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhang, Z., Jiang, J., Wu, X., Zhang, M., Luo, D., Zhang, R., Li, S., He, Y.-W., Bian, H., & Chen, Z. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0683-y · Cited by 51
Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer
Wang, H., Wang, S., Huang, M.-C., Liang, X., Tang, Y.-J., & Tang, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00498 · Cited by 55
Ma, F., Ho, J., Du, H., Fan, X., Wu, X., Wang, Q., Wang, L., Liu, Y., Ba, M., Wang, Y., et al. (2019) · Hematological Oncology · doi:10.1002/hon.2672 · Cited by 52
Self-citationModular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
Sutherland, A. R., Owens, M. N., & Geyer, C. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197222 · Cited by 52
Bechman, N., & Maher, J. F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1857361 · Cited by 51
Yang, M., Wang, L., Ni, M., Neuber, B., Wang, S., Gong, W., Sauer, T., Sellner, L., Schubert, M., Hückelhoven‐Krauss, A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608167 · Cited by 52
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
Hernández-López, A., Téllez‐González, M. A., Mondragón‐Terán, P., & Meneses‐Acosta, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720692 · Cited by 52
Yang, L., Yin, J., Wu, J., Qiao, L., Zhao, E. M., Cai, F., & Ye, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106612118 · Cited by 50
Natural Killer Cell-Mediated Immunotherapy for Leukemia
Allison, M., Mathews, J., Gilliland, T. M., & Mathew, S. O. (2022) · Cancers · doi:10.3390/cancers14030843 · Cited by 50
Tomar, S., Zhang, J., Khanal, M., Hong, J., Venugopalan, A. K., Jiang, Q., Sengupta, M., Miettinen, M., Li, N., Pastan, I. H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0073 · Cited by 50
Sudarsanam, H., Buhmann, R., & Henschler, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.886637 · Cited by 54
Dose fractionation of CAR-T cells. A systematic review of clinical outcomes
Frigault, M. J., Rotte, A., Ansari, A., Gliner, B., Heery, C. R., & Shah, B. D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02540-w · Cited by 52
Li, M., Jiang, P., Wei, S., Wang, J., & Li, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113312 · Cited by 52
ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors
Hong, Y., Walling, B. L., Kim, H.-R., Serratelli, W. S., Lozada, J. R., Sailer, C. J., Amitrano, A. M., Lim, K., Mongre, R. K., Kim, K., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01498-x · Cited by 50
Chimeric antigen receptor macrophages target and resorb amyloid plaques
Kim, A. B., Xiao, Q., Yan, P., Pan, Q., Pandey, G., Grathwohl, S., Gonzales, E. R., Xu, I., Cho, Y., Haecker, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175015 · Cited by 50
Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy
Zhu, B., Yin, H., Zhang, D., Zhang, M., Chao, X., Scimeca, L., & Wu, M.-R. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01153-x · Cited by 50
Mechanisms and management of CAR T toxicity
Ferreri, C. J., & Bhutani, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1396490 · Cited by 56
Murad, J. P., Christian, L., Rosa, R. C. A., Ren, Y., Buckley, A. J., Lee, E. H. J., Lopez, L. S., Park, A. K., Yang, J., Yamaguchi, Y., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01509-2 · Cited by 52
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Saner, F. A. M., Herschtal, A., Nelson, B. H., DeFazio, A., Goode, E. L., Ramus, S. J., Pandey, A., Beach, J. A., Fereday, S., Berchuck, A., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0145-5 · Cited by 51
The Janus Face of Tumor Microenvironment Targeted by Immunotherapy
Buoncervello, M., Gabriele, L., & Toschi, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174320 · Cited by 50
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Alhabbab, R. Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00312 · Cited by 51
Landgraf, K. E., Williams, S. R., Steiger, D., Gebhart, D., Lok, S., Martin, D. W., Roybal, K. T., & Chan, K. (2020) · Communications Biology · doi:10.1038/s42003-020-1021-2 · Cited by 52
Meir, J., Abid, M. A., & Abid, M. B. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.09.016 · Cited by 51
Smith, J. D., Cardwell, L. N., Porciani, D., Nguyen, J. A., Zhang, R., Gallazzi, F., Tata, R. R., Burke, D. H., Daniëls, M. A., & Ulery, B. D. (2018) · Physical Biology · doi:10.1088/1478-3975/aadb68 · Cited by 49
García-Calderón, C. B., Sierro-Martínez, B., García‐Guerrero, E., Sanoja-Flores, L., Muñoz-García, R., Ruiz-Maldonado, V., Jiménez‐León, M. R., Delgado‐Serrano, J., Molinos-Quintana, Á., Guijarro-Albaladejo, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152498 · Cited by 51
Meng, F., Zhang, S., Xie, J., Zhou, Y., Wu, Q., Lu, B., Zhou, S., Zhao, X., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01455-z · Cited by 53
Porter, L. H., Zhu, J. J., Lister, N. L., Harrison, S. G., Keerthikumar, S., Goode, D. L., Urban, R. Q., Byrne, D. J., Azad, A., Vela, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40852-3 · Cited by 50
Shen, Z., Che, X., Zhang, K., Bai, Y., & Deng, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.014 · Cited by 49
Shah, B. D., Cassaday, R. D., Park, J. H., Houot, R., Logan, A. C., Boissel, N., Leguay, T., Bishop, M. R., Topp, M. S., O’Dwyer, K. M., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02532-7 · Cited by 52
Self-citationFoxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming
Niu, C., Wei, H., Pan, X., Wang, Y., Song, H., Li, C., Qie, J., Qian, J., Mo, S., Zheng, W., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.04.008 · Cited by 49
Self-citationKantarjian, H. M., Pui, C., & Jabbour, E. J. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00864-5 · Cited by 49
Candoni, A., Rambaldi, A., Fanin, R. R., Velardi, A., Arcese, W., Ciceri, F., Lazzarotto, D., Lussana, F., Olivieri, J., Grillo, G., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.07.037 · Cited by 49
Lin, G., Zhang, Y., Yu, L., & Wu, D. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11847 · Cited by 49
Jin, K., Du, W., Lan, H., Liu, Y., Mao, C., Du, J., & Mou, X. (2021) · Cancer Science · doi:10.1111/cas.14934 · Cited by 48
Wang, L., Hong, R., Zhou, L., Ni, F., Zhang, M., Zhao, H., Wu, W., Wang, Y., Ding, S., Chang, A. H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702644 · Cited by 49
Self-citationEEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations
Beuchat, I., Danish, H. H., Rubin, D. B., Jacobson, C. A., Robertson, M. S., Vaitkevicius, H., & Lee, J. W. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab174 · Cited by 49
Wayne, A. S., Huynh, V., Hijiya, N., Rouce, R. H., Brown, P. A., Krueger, J., Kitko, C. L., Ziga, E. D., Hermiston, M. L., Richards, M. K., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280678 · Cited by 48
Queudeville, M., Stein, A. S., Locatelli, F., Ebinger, M., Handgretinger, R., Gökbuget, N., Gore, L., Zeng, Y., Gokani, P., Zugmaier, G., et al. (2023) · Cancer · doi:10.1002/cncr.34667 · Cited by 48
B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer
Li, S., Zhang, M., Wang, M., Wang, H., Wu, H., Mao, L., Zhang, M., Li, H., Zheng, J., Ma, P., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01453-7 · Cited by 49
Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond
Aureli, A., Marziani, B., Venditti, A., Sconocchia, T., & Sconocchia, G. (2023) · Cancers · doi:10.3390/cancers15133346 · Cited by 54
Yan, Z., Dong, Y., Qiao, N., Zhang, Y., Wu, W., Zhu, Y., Wang, L., Cheng, S., Xu, P.-P., Zhou, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49495-4 · Cited by 48
Talbot, L. J., Chabot, A., Ross, A. B., Beckett, A., Nguyen, P., Fleming, A. M., Chockley, P. J., Sheppard, H., Wang, J., Gottschalk, S. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3298 · Cited by 48
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts
Short, N. J., Aldoss, I. T., DeAngelo, D. J., Konopleva, M. Y., Leonard, J. T., Logan, A. C., Park, J. H., Shah, B. D., Stock, W., & Jabbour, E. J. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015441 · Cited by 49
Self-citationWang, X., Bórquez-Ojeda, O., Stefanski, J., Du, F., Qu, J., Chaudhari, J., Thummar, K., Zhu, M., Shen, L., Hall, M. J., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.014 · Cited by 48
Self-citationMerker, M., Salzmann‐Manrique, E., Katzki, V., Huenecke, S., Bremm, M., Bakhtiar, S., Willasch, A. M., Jarisch, A., Soerensen, J., Schulz, A., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.03.004 · Cited by 48
Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy
Cao, W., Wei, J., Wang, N., Xu, H., Xiao, M., Huang, L., Cao, Y., Li, C., Xiao, Y., Gu, C., et al. (2020) · Blood · doi:10.1182/blood.2020004907 · Cited by 48
Pabst, T., Joncourt, R., Shumilov, E., Heini, A. D., Wiedemann, G., Legros, M., Seipel, K., Schild, C., Jalowiec, K. A., Taleghani, B. M., et al. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.07.003 · Cited by 50
Li, H., Zhou, X., Wang, G., Hua, D., Li, S., Xu, T., Dong, M., Cui, X., Yang, X., Wu, Y., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab819 · Cited by 50
Textor, A., Grunewald, L., Anders, K., Klaus, A., Schwiebert, S., Winkler, A., Stecklum, M., Rolff, J., Henssen, A. G., Höpken, U. E., et al. (2021) · Cancers · doi:10.3390/cancers13051050 · Cited by 47
Henn, D., Zhao, D., Sivaraj, D., Trotsyuk, A. A., Bonham, C. A., Fischer, K. S., Kehl, T., Fehlmann, T., Greco, A. H., Kussie, H. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40519-z · Cited by 51
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers
Gu, X., Zhang, Y., Zhou, W., Wang, F., Yan, F., Gao, H., & Wang, W. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00542-2 · Cited by 49
Cancer immunotherapy with CAR-T cells – behold the future
Graham, C., Hewitson, R., Pagliuca, A., & Benjamin, R. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-4-324 · Cited by 47
Hu, Y., Wang, J., Wei, G., Yu, J., Luo, Y., Shi, J., Wu, W., Zhao, K., Xiao, L., Zhang, Y., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0403-2 · Cited by 49
Zhao, Y. Q., Liu, Z., Wang, X., Wu, H., Zhang, J., Yang, J., Zhang, F., Liu, L., Long, J., Lu, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0916 · Cited by 47
Self-citationRole of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
Jacome, A. A. D. A., & Eng, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1680636 · Cited by 47
Aldoss, I. T., & Forman, S. J. (2020) · Blood · doi:10.1182/blood.2019002132 · Cited by 48
CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm
Bôle‐Richard, E., Fredon, M., Biichlé, S., Anna, F., Certoux, J.-M., Renosi, F., Tsé, F., Molimard, C., Valmary‐Degano, S., Jenvrin, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0777-1 · Cited by 52
Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer
Le, X., Ferrarotto, R., Wise-Draper, T. M., & Gillison, M. L. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7590 · Cited by 47
Rubinstein, J. D., Krupski, C., Nelson, A. S., O'Brien, M. M., Davies, S. M., & Phillips, C. L. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.07.036 · Cited by 47
Aptamer-Mediated Nanotheranostics for Cancer Treatment: A Review
Ravichandran, G., & Rengan, A. K. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c01785 · Cited by 47
Wendel, P., Reindl, L. M., Bexte, T., Künnemeyer, L., Särchen, V., Albinger, N., Mackensen, A., Rettinger, E., Bopp, T., & Ullrich, E. (2021) · Cancers · doi:10.3390/cancers13061481 · Cited by 48
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival
Julamanee, J., Terakura, S., Umemura, K., Adachi, Y., Miyao, K., Okuno, S., Takagi, E., Sakai, T., Koyama, D., Goto, T., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.038 · Cited by 47
CAR T-cell therapy and critical care
Messmer, A. S., Que, Y., Schankin, C. J., Banz, Y., Bacher, U., Novak, U., & Pabst, T. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01948-2 · Cited by 49
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting
Seitz, C. M., Mittelstaet, J., Atar, D., Hau, J., Reiter, S., Illi, C., Kieble, V., Engert, F., Drees, B., Bender, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2003532 · Cited by 47
Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts
Ellegast, J. M., Alexe, G., Hamze, A., Lin, S., Uckelmann, H. J., Rauch, P. J., Pimkin, M., Ross, L. S., Dharia, N. V., Robichaud, A. L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0956 · Cited by 49
CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar
Chen, K., Liu, M., Wang, J., & Fang, S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9675 · Cited by 49
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
Canedo, G. D. O., Roddie, C., & Amrolia, P. J. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013586 · Cited by 47
Kratzer, B., Köhler, C., Hofer, S., Smole, U., Trapin, D., Iturri, J. J., Pum, D., Kienzl, P., Elbe‐Bürger, A., Gattinger, P., et al. (2018) · Allergy · doi:10.1111/all.13573 · Cited by 46
Nagler, A., Labopin, M., Dholaria, B., Finke, J., Brecht, A., Schanz, U., Niittyvuopio, R., Neubauer, A., Bornhäuser, M., Santarone, S., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15973 · Cited by 46
IL-12 Signaling Promotes TET2-Mediated DNA Demethylation During CD8 T Cell Effector Differentiation
Zebley, C. C., Abdelsamed, H. A., Ghoneim, H. E., Alli, S., Brown, C., Haydar, D., Tian, M., Harris, T. L., McGargill, M. A., Krenciute, G., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109796 · Cited by 45
Altered cancer metabolism and implications for next-generation CAR T-cell therapies
Ramapriyan, R., Vykunta, V. S., Vandecandelaere, G., Richardson, L. G., Sun, J. M., Curry, W. T., & Choi, B. D. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108667 · Cited by 48
Metadata
- Authors
- Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From the Leukemia Service, Department of Medicine (J.H.P., C.S., P.M., R.J.B.), the Michael G. Harris Cell Therapy and Cell Engineering Facility (I.R., X.W., B. Sénéchal, Y.W.), the Center for Cell Engineering (J.H.P., I.R., X.W., R.J.B., M.S.), and the Departments of Epidemiology and Biostatistics (M.G.), Pediatrics (K.J.C.), Neurology (B. Santomasso), Anesthesiology and Critical Care Medicine (E.M.), and Pathology (M.R.), Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Joan...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 449-459
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6637939
- OpenAlex
- W2787621143
- Cited by
- 2,688
- References
- 24
- Citations by year
- 2026: 164 · 2025: 235 · 2024: 306 · 2023: 351 · 2022: 365 · 2021: 403 · 2020: 412 · 2019: 290 · 2018: 156
- FWCI
- 118.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Comprehensive Cancer Network Foundation (Young Investigator Award)
- Emerald Foundation
- National Institute of Health (R01CA138738-05, P01CA059350, P01CA190174-01)
- Leukemia and Lymphoma Society (Career Development Award)
- American Society of Clinical Oncology (Career Development Award)
- Memorial Sloan Kettering Cancer Center Support Grant (P30CA008748)
- Juno Therapeutics
- Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center
- Stand Up To Cancer
- William Lawrence and Blanche Hughes Foundation
- Annual Terry Fox Run for Cancer Research
- Carson Family Charitable Trust
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 CAR T cells, B-cell acute lymphoblastic leukemia, relapsed leukemia, autologous T cell therapy, cytokine release syndrome, neurotoxicity, disease burden, bone marrow blasts, event-free survival, overall survival, long-term outcomes
- MeSH terms
- Adult, Aged, Follow-Up Studies, Humans, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Remission Induction, T-Lymphocytes, Survival Analysis, Cytokines, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
